Cargando…
Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol
Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to explore the efficacy, safety, acceptability and mechanisms of action of 0.01% unpreserved atropine for myopia control in a European population. Methods: MOSAIC is an investigator-led, double-masked, placebo-controlled, ran...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973533/ https://www.ncbi.nlm.nih.gov/pubmed/32002514 http://dx.doi.org/10.12688/hrbopenres.12914.1 |
_version_ | 1783490053083758592 |
---|---|
author | McCrann, Saoirse Flitcroft, Ian Strang, Niall C. Saunders, Kathryn J. Logan, Nicola S. Lee, Samantha Szeyee Mackey, David A. Butler, John S. Loughman, James |
author_facet | McCrann, Saoirse Flitcroft, Ian Strang, Niall C. Saunders, Kathryn J. Logan, Nicola S. Lee, Samantha Szeyee Mackey, David A. Butler, John S. Loughman, James |
author_sort | McCrann, Saoirse |
collection | PubMed |
description | Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to explore the efficacy, safety, acceptability and mechanisms of action of 0.01% unpreserved atropine for myopia control in a European population. Methods: MOSAIC is an investigator-led, double-masked, placebo-controlled, randomised clinical trial (RCT) investigating the efficacy, safety and mechanisms of action of 0.01% atropine for managing progression of myopia. During Phase 1 of the trial, 250 children aged 6-16 years with progressive myopia instil eye drops once nightly in both eyes from randomisation to month 24. No treatment is given during Phase 2 from month 24 to 36 (washout period) for those participants initially randomised to the intervention arm (n=167), during which any potential rebound effects on cessation of treatment will be monitored. All participants initially assigned to the placebo (n=83) crossover to the intervention arm of the study for Phase 2, and from month 24 to 36, instil 0.01% atropine eye drops in both eyes once nightly. Further treatment and monitoring beyond 36 months is planned (Phase 3) and will be designed dependent on the outcomes of Phase 1. Results: The primary outcome measure is cycloplegic spherical equivalent refractive error progression at 24 months. Secondary outcome measures include axial length change as well as the rebound, safety and acceptability profile of 0.01% atropine. Additional analyses will include the mechanisms of action of 0.01% atropine for myopia control. Conclusions: The generalisability of results from previous clinical trials investigating atropine for myopia control is limited by the predominantly Asian ethnicity of previous study populations. MOSAIC is the first RCT to explore the efficacy, safety and mechanisms of action of unpreserved 0.01% atropine in a predominantly White population. Trial registration: ISRCTN: ISRCTN36732601 (04/10/2017), EudraCTdatabase 2016-003340-37 (03/07/2018). |
format | Online Article Text |
id | pubmed-6973533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-69735332020-01-29 Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol McCrann, Saoirse Flitcroft, Ian Strang, Niall C. Saunders, Kathryn J. Logan, Nicola S. Lee, Samantha Szeyee Mackey, David A. Butler, John S. Loughman, James HRB Open Res Study Protocol Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to explore the efficacy, safety, acceptability and mechanisms of action of 0.01% unpreserved atropine for myopia control in a European population. Methods: MOSAIC is an investigator-led, double-masked, placebo-controlled, randomised clinical trial (RCT) investigating the efficacy, safety and mechanisms of action of 0.01% atropine for managing progression of myopia. During Phase 1 of the trial, 250 children aged 6-16 years with progressive myopia instil eye drops once nightly in both eyes from randomisation to month 24. No treatment is given during Phase 2 from month 24 to 36 (washout period) for those participants initially randomised to the intervention arm (n=167), during which any potential rebound effects on cessation of treatment will be monitored. All participants initially assigned to the placebo (n=83) crossover to the intervention arm of the study for Phase 2, and from month 24 to 36, instil 0.01% atropine eye drops in both eyes once nightly. Further treatment and monitoring beyond 36 months is planned (Phase 3) and will be designed dependent on the outcomes of Phase 1. Results: The primary outcome measure is cycloplegic spherical equivalent refractive error progression at 24 months. Secondary outcome measures include axial length change as well as the rebound, safety and acceptability profile of 0.01% atropine. Additional analyses will include the mechanisms of action of 0.01% atropine for myopia control. Conclusions: The generalisability of results from previous clinical trials investigating atropine for myopia control is limited by the predominantly Asian ethnicity of previous study populations. MOSAIC is the first RCT to explore the efficacy, safety and mechanisms of action of unpreserved 0.01% atropine in a predominantly White population. Trial registration: ISRCTN: ISRCTN36732601 (04/10/2017), EudraCTdatabase 2016-003340-37 (03/07/2018). F1000 Research Limited 2019-07-23 /pmc/articles/PMC6973533/ /pubmed/32002514 http://dx.doi.org/10.12688/hrbopenres.12914.1 Text en Copyright: © 2019 McCrann S et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol McCrann, Saoirse Flitcroft, Ian Strang, Niall C. Saunders, Kathryn J. Logan, Nicola S. Lee, Samantha Szeyee Mackey, David A. Butler, John S. Loughman, James Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
title | Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
title_full | Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
title_fullStr | Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
title_full_unstemmed | Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
title_short | Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
title_sort | myopia outcome study of atropine in children (mosaic): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973533/ https://www.ncbi.nlm.nih.gov/pubmed/32002514 http://dx.doi.org/10.12688/hrbopenres.12914.1 |
work_keys_str_mv | AT mccrannsaoirse myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT flitcroftian myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT strangniallc myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT saunderskathrynj myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT logannicolas myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT leesamanthaszeyee myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT mackeydavida myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT butlerjohns myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol AT loughmanjames myopiaoutcomestudyofatropineinchildrenmosaicaninvestigatorleddoublemaskedplacebocontrolledrandomisedclinicaltrialprotocol |